Gemcitabine and cisplatin plus nivolumab as organ-sparing treatment for muscle-invasive bladder cancer: a phase 2 trial (vol 29, pg 2825, 2023)

被引:1
|
作者
Galsky, Matthew D. [1 ,2 ]
Daneshmand, Siamak [3 ]
Izadmehr, Sudeh [1 ]
Gonzalez-Kozlova, Edgar [4 ]
Chan, Kevin G. [5 ]
Lewis, Sara [6 ]
El Achkar, Bassam [6 ]
Dorff, Tanya B. [7 ]
Cetnar, Jeremy Paul [8 ]
Neil, Brock O. [9 ]
D'Souza, Anishka [10 ]
Mamtani, Ronac [11 ]
Kyriakopoulos, Christos [12 ]
Jun, Tomi [13 ,25 ]
Gogerly-Moragoda, Mahalya [1 ]
Brody, Rachel [2 ,14 ]
Xie, Hui [15 ]
Nie, Kai [15 ]
Kelly, Geoffrey [15 ]
Horowitz, Amir [2 ,16 ]
Kinoshita, Yayoi [14 ]
Ellis, Ethan [17 ,18 ]
Nose, Yohei [16 ]
Ioannou, Giorgio [16 ]
Cabal, Rafael [16 ]
Del Valle, Diane M. [16 ]
Haines, G. Kenneth [19 ]
Wang, Li [1 ,20 ]
Mouw, Kent W. [21 ]
Samstein, Robert M. [22 ]
Mehrazin, Reza [23 ]
Bhardwaj, Nina [2 ,15 ,16 ]
Yu, Menggang [24 ]
Zhao, Qianqian [24 ]
Kim-Schulze, Seunghee [2 ,15 ,16 ]
Sebra, Robert [2 ,17 ,18 ]
Zhu, Jun [1 ,20 ]
Gnjatic, Sacha [2 ,15 ,16 ]
Sfakianos, John [23 ]
Pal, Sumanta K. [7 ]
机构
[1] Icahn Sch Med Mt Sinai, Div Hematol & Med Oncol, New York, NY 10029 USA
[2] Icahn Sch Med Mt Sinai, Tisch Canc Inst, New York, NY 10029 USA
[3] Keck Sch Med USC, Dept Urol, Norris Comprehens Canc Ctr, Los Angeles, CA USA
[4] Icahn Sch Med Mt Sinai, Dept Oncol Sci, Tisch Canc Inst, New York, NY 10029 USA
[5] City Hope Comprehens Canc Ctr, Dept Urol, Duarte, CA USA
[6] Icahn Sch Med Mt Sinai, Dept Radiol, Tisch Canc Inst, New York, NY 10029 USA
[7] City Hope Comprehens Canc Ctr, Dept Med Oncol & Therapeut, Duarte, CA USA
[8] Oregon Hlth & Sci Univ, Div Hematol & Med Oncol, Portland, OR 97201 USA
[9] Univ Utah, Dept Urol, Salt Lake City, UT USA
[10] Keck Sch Med USC, Div Hematol & Med Oncol, Norris Comprehens Canc Ctr, Los Angeles, CA USA
[11] Univ Penn, Abramson Canc Ctr, Div Hematol & Med Oncol, Philadelphia, PA 19104 USA
[12] Univ Wisconsin, Div Hematol & Med Oncol, Carbone Canc Ctr, Madison, WI USA
[13] Genentech Inc, San Francisco, CA USA
[14] Icahn Sch Med Mt Sinai, Tisch Canc Inst, Dept Pathol, New York, NY 10029 USA
[15] Icahn Sch Med Mt Sinai, Human Immune Monitoring Ctr, New York, NY 10029 USA
[16] Icahn Sch Med Mt Sinai, Precis Immunol Inst, New York, NY 10029 USA
[17] Icahn Sch Med Mt Sinai, Dept Genet & Genom Sci, New York, NY 10029 USA
[18] Icahn Sch Med Mt Sinai, Icahn Inst Data Sci & Genom Technol, New York, NY 10029 USA
[19] Icahn Sch Med Mt Sinai, Dept Pathol Mol & Cell Based, New York, NY 10029 USA
[20] Gene Dx, Stamford, CT USA
[21] Harvard Med Sch, Brigham & Womens Hosp, Dana Farber Canc Inst, Dept Radiat Oncol, Boston, MA 02115 USA
[22] Icahn Sch Med Mt Sinai, Dept Radiat Oncol, Tisch Canc Inst, New York, NY 10029 USA
[23] Icahn Sch Med Mt Sinai, Dept Urol, Tisch Canc Inst, New York, NY 10029 USA
[24] Univ Wisconsin, Carbone Canc Ctr, Dept Biostat & Med Informat, Madison, WI USA
[25] Icahn Sch Med Mt Sinai, New York, NY 10029 USA
关键词
D O I
10.1038/s41591-024-02814-0
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
引用
收藏
页码:1211 / 1211
页数:1
相关论文
共 50 条
  • [21] Neoadjuvant Dose-dense Gemcitabine and Cisplatin in Muscle-Invasive Bladder Cancer: Results of a Phase 2 Trial
    Anari, Fern
    O'Neill, John
    Choi, Woonyoung
    Chen, David Y. T.
    Haseebuddin, Mohammed
    Kutikov, Alexander
    Dulaimi, Essel
    Alpaugh, R. Katherine
    Devarajan, Karthik
    Greenberg, Richard E.
    Bilusic, Marijo
    Wong, Yu-Ning
    Viterbo, Rosalia
    Hoffman-Censitsc, Jean H.
    Lallas, Costas D.
    Trabulsic, Edouard J.
    Smaldone, Marc
    Geynisman, Daniel M.
    Zibelman, Matthew
    Lin, Jianqing
    Kelly, W. Kevin
    Uzzo, Robert
    McConkey, David
    Plimack, Elizabeth R.
    EUROPEAN UROLOGY ONCOLOGY, 2018, 1 (01): : 54 - 60
  • [22] Camrelizumab in combination with gemcitabine plus cisplatin as neoadjuvant therapy for muscle-invasive bladder cancer
    Xing, N.
    Han, S.
    Jiang, J.
    Xu, W.
    Shi, B.
    Ping, H.
    Ji, Z.
    Ma, Q.
    Wang, H.
    Chen, S.
    Wang, W.
    Fan, X.
    Zhou, Q.
    Zhang, W.
    ANNALS OF ONCOLOGY, 2021, 32 : S714 - S714
  • [23] Is neoadjuvant chemotherapy with gemcitabine plus cisplatin beneficial in patients with muscle-invasive bladder cancer?
    Yafi, Faysal A.
    Kassouf, Wassim
    EXPERT REVIEW OF ANTICANCER THERAPY, 2009, 9 (06) : 747 - 752
  • [24] Radical cystectomy versus organ-sparing trimodality treatment in muscle-invasive bladder cancer: A systematic review of clinical trials
    Arcangeli, G.
    Strigari, L.
    Arcangeli, S.
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2015, 95 (03) : 387 - 396
  • [25] Multicenter Prospective Phase II Trial of Neoadjuvant Dose-Dense Gemcitabine Plus Cisplatin in Patients With Muscle-Invasive Bladder Cancer
    Iyer, Gopa
    Balar, Arjun V.
    Milowsky, Matthew I.
    Bochner, Bernard H.
    Dalbagni, Guido
    Donat, S. Machele
    Herr, Harry W.
    Huang, William C.
    Taneja, Samir S.
    Woods, Michael
    Ostrovnaya, Irina
    Al-Ahmadie, Hikmat
    Arcila, Maria E.
    Riches, Jamie C.
    Meier, Andreas
    Bourque, Caitlin
    Shady, Maha
    Won, Helen
    Rose, Tracy L.
    Kim, William Y.
    Kania, Brooke E.
    Boyd, Mariel E.
    Cipolla, Catharine K.
    Regazzi, Ashley M.
    Delbeau, Daniela
    McCoy, Asia S.
    Vargas, Hebert Alberto
    Berger, Michael F.
    Solit, David B.
    Rosenberg, Jonathan E.
    Bajorin, Dean F.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (19) : 1949 - +
  • [26] Comparison between neoadjuvant and adjuvant gemcitabine plus cisplatin chemotherapy for muscle-invasive bladder cancer
    Matsubara, Nobuaki
    Mukai, Hirofumi
    Naito, Yoichi
    Nezu, Masahiko
    Itoh, Kuniaki
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2013, 9 (04) : 310 - 317
  • [27] Neoadjuvant gemcitabine-cisplatin plus tislelizumab in persons with resectable muscle-invasive bladder cancer: a multicenter, single-arm, phase 2 trial
    Li, Kaiwen
    Zhong, Wenlong
    Fan, Jinhai
    Wang, Shaogang
    Yu, Dexin
    Xu, Tao
    Lyu, Jiaju
    Wu, Shaoxu
    Qin, Tao
    Wu, Zhuo
    Xu, Longhao
    Wu, Kaijie
    Liu, Zheng
    Hu, Zhiquan
    Li, Fan
    Wang, Jinyou
    Wang, Qi
    Min, Jie
    Zhang, Zhiqiang
    Yu, Luping
    Ding, Sentai
    Huang, Longfei
    Zhao, Tingting
    Huang, Jian
    Lin, Tianxin
    NATURE CANCER, 2024, 5 (10) : 1465 - 1478
  • [28] Organ-sparing Chemoradiotherapy: a viable Alternative to initial Cystectomy for patients with Muscle-invasive bladder cancer compared to Radiotherpay
    Weiss, C.
    Sauer, R.
    STRAHLENTHERAPIE UND ONKOLOGIE, 2012, 188 (08) : 713 - 716
  • [29] Re: Multicenter Prospective Phase II Trial of Neoadjuvant Dose-Dense Gemcitabine plus Cisplatin in Patients with Muscle-Invasive Bladder Cancer
    Chang, Sam S.
    JOURNAL OF UROLOGY, 2020, 203 (04): : 659 - 660
  • [30] Re: Multicenter Prospective Phase II Trial of Neoadjuvant Dose-dense Gemcitabine Plus Cisplatin in Patients with Muscle-invasive Bladder Cancer
    Voskuilen, Charlotte S.
    van der Heijden, Michiel S.
    van Rhijn, Basw. G.
    EUROPEAN UROLOGY, 2019, 76 (06) : 870 - 871